Zura Bio Ltd. Files 8-K: Regulation FD Disclosure & Exhibits

Ticker: ZURA · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1855644

Zura Bio Ltd 8-K Filing Summary
FieldDetail
CompanyZura Bio Ltd (ZURA)
Form Type8-K
Filed DateMar 11, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001, $11.50
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

Zura Bio filed an 8-K with disclosures and financials. Check for updates.

AI Summary

On March 11, 2024, Zura Bio Ltd. filed an 8-K report detailing a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly JATT Acquisition Corp., is incorporated in the Cayman Islands and operates in the biological products sector. Its principal executive offices are located in Henderson, Nevada.

Why It Matters

This filing provides important updates and disclosures for investors regarding Zura Bio Ltd.'s regulatory compliance and financial reporting.

Risk Assessment

Risk Level: low — This is a routine regulatory filing and does not indicate any immediate material changes or risks.

Key Players & Entities

  • Zura Bio Limited (company) — Registrant
  • JATT Acquisition Corp. (company) — Former company name
  • 20240311 (date) — Date of report
  • 0001104659-24-032636 (filing_id) — Accession Number
  • 001-40598 (company_id) — Commission File Number

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.

What was Zura Bio Ltd.'s former name?

Zura Bio Ltd.'s former name was JATT Acquisition Corp.

In which jurisdiction is Zura Bio Ltd. incorporated?

Zura Bio Ltd. is incorporated in the Cayman Islands.

What is the business address of Zura Bio Ltd.?

The business address of Zura Bio Ltd. is 1489 W. Warm Springs Rd. #110, Henderson, Nevada 89014.

What is Zura Bio Ltd.'s Standard Industrial Classification code?

Zura Bio Ltd.'s Standard Industrial Classification code is 2836, for Biological Products (No Diagnostic Substances).

Filing Stats: 717 words · 3 min read · ~2 pages · Grade level 13.1 · Accepted 2024-03-11 06:04:53

Key Financial Figures

  • $0.0001 — ed Class A Ordinary Shares, par value $0.0001 per share ZURA The Nasdaq Stock Mar
  • $11.50 — Ordinary Share at an exercise price of $11.50 per share ZURAW The Nasdaq Stock Ma

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On March 11, 2024, representatives of Zura Bio Limited, a Cayman Islands exempted company (the "Company"), began making presentations to banks and analysts using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.1 (the "Investor Presentation"), which is incorporated herein by reference. The Company has filed the Investor Presentation on its website and expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others during the fiscal year ending December 31, 2024. By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or specifically incorporates it by reference into a filing

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Number Description 99.1 Investor Presentation dated March 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 11, 2024 ZURA BIO LIMITED By: /s/ Kim Davis Kim Davis Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.